|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 238.10 EUR | -0.50% |
|
+1.06% | -0.21% |
| 15/07 | Where would AI lead Pharma in the long run? |  |
| 13/07 | Antengene Receives $60 Million Milestone in UCB Licensing Deal | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB | Biopharmaceuticals | -0.50% | +1.06% | -0.21% | +37.39% | +168.61% | 52.13B |  |  | |
- Stock Market
- Stocks
- UCB Stock
- Charts UCB
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
